Evaluation of cardiovascular risk in a lung cancer screening cohort: what value does it bring?

Guariglia A.; Davies IJ.; Kanellakis NI.

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Evaluation of cardiovascular risk in a lung cancer screening cohort: what value does it bring?

Guariglia A., Davies IJ., Kanellakis NI.

There is a significant opportunity to improve cardiovascular disease (CVD) outcomes in lung cancer screening cohorts with a low-cost, noninvasive assessment of CVD risk, alongside existing assessments https://bit.ly/3a6Ha41.

Original publication

DOI

10.1183/20734735.0204-2020

Type

Journal article

Journal

Breathe (Sheffield, England)

Publication Date

12/2020

Volume

Addresses

Laboratory of Pleural and Lung Cancer Translational Research, Nuffield Dept of Medicine, University of Oxford, Oxford, UK.